Re: Brian I. Rini, Thomas Powles, Michael B. Atkins, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019;393:2404–15: Putting IMmotion into motion: Personalizing frontline treatment for metastatic renal cell carcinoma Correspondence
| Author: | Singla, N. |
| Title: | Re: Brian I. Rini, Thomas Powles, Michael B. Atkins, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019;393:2404–15: Putting IMmotion into motion: Personalizing frontline treatment for metastatic renal cell carcinoma |
| Keywords: | cancer survival; treatment response; gene mutation; bevacizumab; sunitinib; drug efficacy; letter; cancer immunotherapy; progression free survival; gene expression; antiangiogenic therapy; open study; kidney metastasis; personalized medicine; randomized controlled trial (topic); phase 3 clinical trial (topic); comparative effectiveness; multicenter study (topic); intention to treat analysis; human; priority journal; atezolizumab |
| Journal Title: | European Urology |
| Volume: | 77 |
| Issue: | 6 |
| ISSN: | 0302-2838 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2020-06-01 |
| Start Page: | e168 |
| End Page: | e169 |
| Language: | English |
| DOI: | 10.1016/j.eururo.2019.09.015 |
| PUBMED: | 31676127 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Letter -- Export Date: 1 July 2020 -- Source: Scopus |
